Research programme: monoclonal antibodies-hyaluronic acid complex - AlchemiaAlternative Names: HA-monoclonal antibodies
Latest Information Update: 25 Nov 2015
At a glance
- Originator Alchemia
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Nov 2015 Preclinical trials in Cancer in Australia (Parenteral)
- 07 May 2010 Early research in Cancer in Australia (Parenteral)